Rita Nanda, MD

Rita Nanda, MD, specializes in the treatment of all forms of breast cancer. Dr. Nanda’s practice focuses on women with triple-negative, hereditary, locally advanced and metastatic breast cancers. She is a strong advocate of using chemotherapy prior to surgery (neoadjuvant chemotherapy) to better understand how an individual's tumor responds to therapy, so that treatment can be tailored to each patient's unique case.

Dr. Nanda’s research interests include identifying new and better treatments for the management of breast cancer. She leads the UChicago Medicines breast cancer clinical trial program. She has extensive knowledge of clinical trials and new therapies in development for all forms of advanced breast cancer. She serves as a principal investigator for the Translational Breast Cancer Research Consortium (TBCRC) and the I-SPY 2 Clinical Trial Network. 

Dr. Nanda’s research has been funded by the National Institutes of Health (NIH), the Department of Defense Breast Cancer Research Program, the Doris Duke Charitable Foundation, the Susan G. Komen Foundation, and the Metastatic Breast Cancer Network. She currently serves as a co-principal investigator on the University of Chicago’s Interdisciplinary Cancer Health Disparities P20 SPORE.